Esophageal Neoplasms Clinical Trials

23 recruiting

Esophageal Neoplasms Trials at a Glance

24 actively recruiting trials for esophageal neoplasms are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Houston, Taipei, and Shanghai. Lead sponsors running esophageal neoplasms studies include Instituto do Cancer do Estado de São Paulo, Merck Sharp & Dohme LLC, and Taipei Veterans General Hospital, Taiwan.

Browse esophageal neoplasms trials by phase

Treatments under study

About Esophageal Neoplasms Clinical Trials

Looking for clinical trials for Esophageal Neoplasms? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting

Mayo Clinic Upper Digestive Disease Survey

Esophageal CancerEsophagus CancerEsophageal Neoplasms+6 more
Mayo Clinic1,000 enrolled1 locationNCT02530983
Recruiting
Not Applicable

Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer

Esophageal NeoplasmsLung Neoplasm
Taipei Veterans General Hospital, Taiwan200 enrolled2 locationsNCT05875870
Recruiting
Not Applicable

Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer

Esophageal Neoplasms
Fudan University142 enrolled1 locationNCT07272382
Recruiting
Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting

Endoscopic Resection of Gastrointestinal Neoplasms

Esophageal NeoplasmsColonic NeoplasmsEndoscopic Mucosal Resection+3 more
Azienda USL Reggio Emilia - IRCCS2,000 enrolled1 locationNCT04780256
Recruiting

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
Yonsei University1,200 enrolled1 locationNCT07035587
Recruiting
Phase 1Phase 2

HTL0039732 in Participants With Advanced Solid Tumours

SarcomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms+11 more
Cancer Research UK150 enrolled5 locationsNCT05944237
Recruiting
Phase 3

Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy

Esophageal Neoplasms
Hecheng Li M.D., Ph.D244 enrolled6 locationsNCT04513418
Recruiting
Not Applicable

Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.

Esophageal NeoplasmsDysphagia
Instituto do Cancer do Estado de São Paulo34 enrolled1 locationNCT06070376
Recruiting
Not Applicable

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Esophageal NeoplasmsHyaluronic AcidEndoscopic Mucosal Resection
Instituto do Cancer do Estado de São Paulo30 enrolled1 locationNCT06077981
Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

Gastric CancerEsophageal NeoplasmsGastric Adenocarcinoma+6 more
Western Sydney Local Health District500 enrolled1 locationNCT05804331
Recruiting

Rehabilitation and Recovery for Persons with Esophageal or Gastric Cancer

Esophageal CancerGastric CancerEsophageal Neoplasms+1 more
Region Skane100 enrolled1 locationNCT05698992
Recruiting
Phase 2

Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms
Hebei Medical University Fourth Hospital67 enrolled1 locationNCT06646588
Recruiting

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers

Esophageal Neoplasms
University Hospital, Ghent100 enrolled1 locationNCT05688176
Recruiting
Phase 3

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences436 enrolled1 locationNCT06086457
Recruiting

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

Esophageal NeoplasmsBrain MetastasesEsophagectomy
Universitaire Ziekenhuizen KU Leuven10,000 enrolled8 locationsNCT04654975
Recruiting
Not Applicable

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

Head and Neck NeoplasmsEsophageal NeoplasmsNeoplasms+6 more
Taipei Veterans General Hospital, Taiwan20 enrolled1 locationNCT06365866